Skip to content
Sign in
Artwork for Explain It to Me Please
BusinessInvesting

Explain It to Me Please

Tim Baker

Breaking down business strategies and financial reports of companies I follow. Not financial advise, not investment advise, AI audio analysis from AI-generated financial reports looking at the latest financial reports from SEC filings, investor relations content, management comments, analyst reports and business and industry publications that are publicly available..

Play
Open in
  • 77 episodes
  • Avg 42 min
  • English

Episodes 77

NewestOldestLongest
All20Unplayed20In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • S2026 · E200
    November 6 · 41 min

    2026Q3 Tempus AI Inc. (TEM)

    Tempus AI operates a dual-engine business model at the intersection of genomic sequencing, precision oncology, and artificial intelligence. The company aims to construct the world’s largest library of clinical and molecular data and operationalize that data to personalize patient care and accelerate therapeutic discovery. The business is bifurcated into two highly synergistic segments: Diagnostics and Data and Applications. Primary Businesses and Operations: Diagnostics: Tempus provides next-generation sequencing (NGS) and molecular profiling directly to oncologists and pathologists. Its core assays include xT (a 648-gene solid tumor DNA assay), xR (a whole-transcriptome RNA solid tumor assay), xF (a liquid biopsy assay), and xM (a methylation-based assay for minimal residual disease detection)7. This segment operates as the data-gathering engine. While gross margins in Diagnostics are solid (historically ~50-60%), the true value lies in the data generated from every test. Data and Applications: Tempus anonymizes, structures, and harmonizes the clinical and genomic data gathered by the Diagnostics division, packaging it into a proprietary, multimodal database. This data is then licensed to biopharmaceutical giants (e.g., AstraZeneca, GSK, Pfizer, BioNTech) to optimize clinical trial design, identify novel biomarkers, and create synthetic control arms9. This segment operates essentially as a high-margin Data-as-a-Service (DaaS) business. Industry Trends, Competitive Trends, and Market Potential (TAM): The total addressable market (TAM) for targeted sequencing, resequencing, and minimal residual disease (MRD) monitoring is experiencing secular tailwinds. The targeted sequencing market is projected to reach $27.37 billion by 2030, compounding at 22.78% annually11. The industry trend is moving decisively from tissue-based biopsies to liquid biopsies and serial MRD testing, which allows oncologists to monitor cancer recurrence from a simple blood draw. Tempus's pending acquisition of Personalis and its NeXT Personal assay (an ultra-sensitive, whole-genome, tissue-informed MRD test) is a direct strategic maneuver to capture market share in this high-frequency testing vertical Economic Moat: Tempus benefits from a profound data network effect. The barrier to entry in the Data and Applications segment is insurmountable for traditional diagnostic labs; a competitor would need to sequence hundreds of thousands of patients, build complex electronic health record (EHR) integrations to extract longitudinal clinical outcome data, and develop the AI infrastructure to harmonize the two. Furthermore, Tempus is actively defending its intellectual property, leveraging patent portfolios to protect its algorithmic models, establishing a deep, structural moat.

  • S2027 · E18
    October 31 · 41 min

    2027Q1 Microsoft Corporation (MSFT)

    Microsoft operates as a highly integrated technology conglomerate, historically functioning across Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. Following the fiscal 2027 reorganization, the "Agents and Infra" segment serves as the primary growth engine, generating $76.8 billion in the first quarter of fiscal 2027 (a 25% year-over-year increase), while the "Devices and Consumer" segment acts as a mature, albeit contracting, cash generator, producing $15.48 billion (a 3% year-over-year decrease) The industry is undergoing a structural shift from traditional cloud computing to generative AI and agentic computing architectures. The total addressable market (TAM) for cloud infrastructure has expanded significantly as enterprises seek to train and deploy proprietary models. Microsoft’s competitive moat relies on high switching costs inherent in its enterprise software suite (Microsoft 365) and deep network effects within its developer and cloud ecosystems (GitHub, Azure). The deployment of Microsoft 365 Copilot, which recently surpassed 30 million paid seats, serves to entrench enterprise customers deeper into the Microsoft ecosystem, raising the barriers to entry for competitors attempting to dislodge legacy productivity workflows9. However, the cost of servicing this expanded TAM has escalated, leading to structurally lower gross margins for the cloud segment, which declined to 66% in the latest quarter due to the sales mix shifting heavily toward capital-intensive AI workloads

  • S2026 · E199
    October 31 · 37 min

    2026Q3 Intel Corporation (INTC)

    Intel operates as a vertically integrated semiconductor design and manufacturing conglomerate, primarily divided into Intel Products (comprising the Client Computing and Physical AI Group [CCPG] and Data Center and AI [DCAI]) and Intel Foundry. The fundamental moat that historically protected Intel's x86 processor dominance has deteriorated structurally over the past five years due to internal execution delays, process node stumbles, and the rise of ARM architecture and accelerated computing (GPUs) pioneered by competitors Sales trends over the five-year evaluation horizon reflect a severe top-line contraction. From a peak revenue of $79.02 billion in fiscal year 2021, revenue degraded to $52.85 billion by fiscal year 202514. Profitability has similarly collapsed; gross margins, which stood at 55.45% in 2021, fell to 36.56% in 2025, driven by immense capital expenditures, lower factory utilization, and the aggressive pricing required to defend market share. The Intel Foundry segment remains a profound drag on consolidated profitability, recording a $13.0 billion operating loss in 2024 (its first fully reported year under the new segmentation) and continuing to post deep operating losses, including a $1.85 billion loss in the third quarter of 2026 Intel's geographic revenue distribution has undergone a radical transformation, demonstrating deep vulnerabilities to geopolitical fracturing. In 2021, the United States accounted for a minority of sales, but by 2025, U.S. revenue concentration surged to 39.24% ($15.76 billion)16. Conversely, revenue from China (including Hong Kong), which constituted 29.25% of sales in 2024, dropped to 0% in 2025, reflecting the devastating impact of U.S. export controls and the decoupling of the global technology supply chain.

  • S2026 · E198
    October 30 · 55 min

    2026Q3 Corning Incorporated (GLW)

    Corning operates as a diversified, global materials science conglomerate, leveraging proprietary capabilities in glass science, ceramic science, and optical physics. Effective in the first quarter of fiscal year 2026, management realigned its reporting structure to better reflect resource allocation and its "Springboard" growth plan. The company now reports under four primary segments: Optical Communications, Glass Innovations (a combination of the former Display Technologies and Specialty Materials segments), Automotive, and Solar (encompassing Hemlock Semiconductor Group, solar wafers, and modules). Remaining operations are classified under Life Sciences and Emerging Growth Businesses Industry Trends and Overall Market Potential (TAM): The fundamental growth engine for Corning is the Optical Communications segment, which has aggressively transitioned from traditional telecommunications carrier networks to hyperscale data center infrastructure. The Total Addressable Market (TAM) is currently expanding exponentially due to the physical limitations of copper wire in generative artificial intelligence (Gen AI) applications. Generative AI architectures, specifically GPU training clusters, operate at extreme thermal limits and require massive bandwidth. The shift from electrical interconnects to optical fiber reduces power consumption per bit transmitted by up to 65% in co-packaged optics scenarios17. The market potential is anchored by the projected $690 billion in capital expenditures by the top five hyperscalers (Amazon, Google, Microsoft, Meta, Oracle) through 2026 Competitive Trends and Economic Moat: Corning possesses a "Wide Moat" supported by immense capital barriers to entry, steep switching costs, and a portfolio of over 12,000 active patents worldwide20. In the Glass Innovations segment, the moat is built upon the proprietary "fusion-draw" manufacturing process, which yields glass substrates with pristine surface quality and extreme thinness without the need for post-production polishing21. In the Optical segment, Corning's moat rests on its SMF-28 Ultra fiber, which utilizes nanoStructures technology to bend light tightly without signal loss (ITU-T G.657 compliant), an essential characteristic for the dense cabling required in AI server racks Primary Business Segments and Profitability Trends: Optical Communications: Represents the largest share of revenue and profit. Driven by multi-billion-dollar hyperscaler supply agreements (including a notable partnership with Amazon AWS), this segment utilizes high-density optical fiber to resolve data center bottlenecks Glass Innovations: Highly cyclical but highly profitable. It provides advanced flat glass substrates for LCD and OLED displays. The segment relies on precise capacity management and price hikes to maintain margins amidst cyclical consumer electronics demand and currency fluctuations Solar: A strategic domestic on-shoring initiative. Hemlock Semiconductor is the sole U.S.-headquartered producer of hyper-pure polysilicon27. While revenue is growing rapidly, the segment operates at a net loss due to the friction of ramping up new capital-intensive facilities. Automotive & Life Sciences: These act as mature, cash-flowing stabilizers, producing ceramic substrates for emissions control and specialized laboratory consumables28.

  • S2026 · E197
    October 30 · 17 min

    2026Q3 Alphabet Inc. (GOOGL)

    Alphabet operates a diversified business model, primarily segmented into Google Services, Google Cloud, and Other Bets. The Google Services segment encompasses Search, YouTube, Google Network, Subscriptions, Platforms, and Devices, generating the vast majority of consolidated revenue and operating income8. Google Cloud includes infrastructure and platform services, enterprise collaboration tools (Google Workspace), and the sale of Tensor Processing Unit (TPU) hardware systems8. The Other Bets segment functions as a venture incubation arm, containing early-stage businesses such as Waymo (autonomous driving) and Verily (life sciences) The company has sustained a highly robust top-line growth trajectory, with total revenue expanding from $257.6 billion in fiscal year 2021 to $402.8 billion in fiscal year 2025, representing a compound annual growth rate (CAGR) of 11.8%11. Gross margins have experienced moderate structural compression, moving from 56.9% in 2021 to 51.9% in 202516. This compression is driven by the escalating costs of technical infrastructure, accelerated data center depreciation, and the transition toward higher-cost AI compute requirements16. Despite declining gross margins, operating margins expanded from 30.5% in 2021 to 34.6% in 2025, a result of aggressive cost-optimization efforts, headcount rationalization, and the rapid scaling of Google Cloud's profitability Google Cloud has emerged as the primary growth engine for the conglomerate. Driven by insatiable enterprise demand for AI infrastructure, Cloud revenue reached $30.71 billion in Q3 2026, representing a 103% year-over-year increase4. This segment benefits significantly from the sale and deployment of custom silicon. The TPU v5p and the newly introduced v6e Trillium chips provide structural cost advantages over pure-play GPU architectures for specific training and inference workloads18. Estimates suggest that on a three-year committed usage basis, the Trillium TPU can execute specific language model inference tasks at a materially lower cost per token compared to commercially available alternatives, solidifying Alphabet's pricing power in the enterprise cloud market Alphabet's economic moat is secured by insurmountable data scale, an entrenched consumer ecosystem across Android and Chrome, and proprietary silicon infrastructure. The total addressable market (TAM) for AI and cloud infrastructure is projected to exceed $1.4 trillion globally by 2032, providing a massive runway for capital deployment21. The company's barriers to entry were recently bolstered by the October 2026 publication of research detailing the "Willow" quantum computing chip. Published in the journal Science, the Willow architecture utilizes a process termed "magic state cultivation" to achieve a 40-fold reduction in quantum error rates, achieving 99.99% logical fidelity22. This theoretical breakthrough represents a formidable long-term moat in the emerging quantum computing sector. Alphabet's balance sheet remains highly liquid but is undergoing rapid structural leveraging. Cash, cash equivalents, and marketable securities totaled $265.1 billion as of September 30, 20268. However, to fund its unprecedented AI data center buildout without fully depleting offshore cash reserves, total debt skyrocketed from $48.5 billion in December 2025 to $125.1 billion in September 20268. This alters the company's traditional debt-free profile and introduces higher fixed interest costs into the income statement.

  • S2026 · E196
    October 28 · 50 min

    2026Q3 Medpace Holdings, Inc. (MEDP)

    Medpace Holdings, Inc. operates within the global clinical Contract Research Organization (CRO) industry, providing scientifically driven, outsourced clinical development services to biotechnology, pharmaceutical, and medical device companies1. The CRO sector is a critical pillar of the global life sciences ecosystem, enabling biopharmaceutical sponsors to navigate complex multi-phase clinical trials (Phases I through IV) and stringent global regulatory approval frameworks overseen by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and international equivalents1 According to industry benchmarks disclosed in peer regulatory filings (such as IQVIA Holdings Inc.'s Form 10-K for the year ended December 31, 2025), global biopharmaceutical spending on research and development (R&D) totaled approximately $199.0 billion in 202513. Excluding preclinical discovery, the addressable clinical development spending market reached approximately $159.0 billion in 2025, up markedly from $99.0 billion in 202313. Of this $159.0 billion clinical development market, outsourced CRO penetration approaches 47%, representing a direct outsourced clinical CRO Total Addressable Market (TAM) of approximately $75.0 billion in 2025, compared to $50.0 billion in 202313. Furthermore, global pharmaceutical revenues reached $1.94 trillion in 2025, with emerging markets projected to expand at a 5% to 8% compound annual growth rate (CAGR) through 2030, driving sustained downstream demand for global multi-site clinical trial execution Within this $75.0 billion outsourced clinical TAM, the industry bifurcates into two distinct operational models1. The first is the Functional Service Provider (FSP) and large-cap hybrid model, which is utilized predominantly by top-20 global pharmaceutical companies that maintain internal clinical management infrastructure and outsource discrete functional tasks, such as clinical monitoring or biostatistics, to mega-CROs like IQVIA, ICON plc, PPD (Thermo Fisher Scientific), and Fortrea Holdings11. The second is the full-service outsourced clinical model, utilized primarily by small- and mid-sized biotechnology companies (firms with less than $250 million in annual revenue or emerging pre-commercial pipelines) that lack internal clinical trial execution teams and require an end-to-end partner to design, manage, and execute the entire clinical trial lifecycle

  • S2026 · E195
    October 28 · 32 min

    2026Q3 Meta Platforms Inc. (META)

    Meta Platforms, Inc. operates the world's largest social networking and digital communications ecosystem, organized into two reportable operating segments: Family of Apps (FoA) and Reality Labs (RL) Family of Apps (FoA): Encompasses Facebook, Instagram, Messenger, WhatsApp, and Threads, alongside consumer and enterprise AI offerings including the Muse personal AI agent and Meta One subscription services1. FY2025 Performance: Generated $198.76 billion in revenue (98.9% of consolidated revenue) and $102.47 billion in operating income, representing a 51.6% segment operating margin 9M 2026 Performance: Generated $180.44 billion in revenue (+29.0% YoY) and $67.41 billion in operating income Revenue Drivers: Substantially all revenue is derived from digital advertising ($63.06 billion or 97.6% of consolidated revenue in Q3 2026)1, supplemented by FoA Other revenue ($1.10 billion in Q3 2026, +59.0% YoY) propelled by WhatsApp Business paid messaging and Meta One subscriptions (surpassing 15 million paid subscriptions and trials in Q3 2026) Reality Labs (RL): Encompasses augmented, mixed, and virtual reality hardware (Meta Quest headsets and Ray-Ban Meta AI Glasses), operating systems, software, and content1. FY2025 Performance: Generated $2.22 billion in revenue against an operating loss of $19.19 billion 9M 2026 Performance: Recorded $1.28 billion in revenue (+1.9% YoY, as AI glasses demand offset lower Quest VR sales) and an operating loss of $12.78 billion Outlook & Cumulative Losses: Management projects full-year 2026 operating losses of $19.0 billion, moderating to approximately $15.0 billion in FY2027 as capital shifts toward core AI and superintelligence1. Cumulative operating losses from FY2021 through Q3 2026 exceed $89.6 billion

  • S2027 · E17
    October 27 · 43 min

    2027Q1 Medtronic PLC

    Founded in 1949 and domiciled in Galway, Ireland (with principal operational headquarters in Minneapolis, Minnesota), Medtronic plc is the world's largest standalone medical technology company by revenue, serving healthcare systems, physicians, clinicians, and over 82 million patients annually across more than 150 countries. Employing over 95,000 personnel globally, Medtronic develops, manufactures, and markets device-based medical therapies and services that address chronic cardiovascular, neurological, surgical, and metabolic conditions. Beginning in Q4 FY2026 and formalized in Q1 FY2027 following the March 2026 IPO of MiniMed Group, Inc., Medtronic reorganized its core operations into three main reportable segments while reporting the Diabetes Operating Segment separately pending complete divestiture: Cardiovascular Portfolio: Generated $3,927M in Q1 FY2027 and $13,977M in FY2026, representing Medtronic's largest growth engine. Neuroscience Portfolio: Generated $2,678M in Q1 FY2027 and $10,275M in FY2026, structured across cranial, spinal, neurovascular, and neuromodulation therapies. Medical Surgical Portfolio: Generated $2,279M in Q1 FY2027 and $8,850M in FY2026, focused on surgical instrumentation, endoscopy, and monitoring platforms. Diabetes Operating Segment (MiniMed): Generated $843M in Q1 FY2027 and $3,100M on a standalone basis in FY2026 through 90.03%-owned subsidiary MiniMed Group, Inc.

  • S2026 · E193
    October 25 · 41 min

    2026Q3 Space Exploration Technologies Corp. (SPCX)

    Space Exploration Technologies Corp. operates as a vertically integrated conglomerate, structurally divided into three primary segments: Space, Connectivity, and Super Intelligence (SI). The interplay between these segments forms a robust economic moat, where launch cost advantages subsidize orbital network deployment, which in turn generates the capital required to fund frontier artificial intelligence infrastructure1 The Space segment designs, manufactures, and operates reusable launch vehicles. The fundamental driver of long-term profitability within this segment is the Starship super-heavy launch vehicle, powered by the newly iterative Raptor 3 engine20. The Raptor 3 achieves a thrust-to-weight ratio (TWR) of 183.6, generating 280 tonnes-force of thrust at sea level with a specific impulse of 350 seconds, all while reducing engine mass to 1,525 kilograms21. By eliminating heavy external heat shields and optimizing additive manufacturing, these engines allow Starship to target a fully reusable payload capacity exceeding 100 metric tons to Low Earth Orbit (LEO)20. Economic models suggest that if rapid and complete reusability is achieved, the marginal cost to deliver payloads to orbit could collapse to below $100 per kilogram, fundamentally disintermediating legacy aerospace competitors The Connectivity segment, operating primarily under the Starlink brand, manages a constellation of over 11,100 LEO satellites serving 13.6 million consumer and enterprise subscribers across 174 markets1. The segment is currently pivoting toward Direct-to-Cell (D2C) mobile services utilizing 3GPP Release 17 Non-Terrestrial Network (NTN) standards. To connect unmodified terrestrial smartphones directly to LEO satellites moving at 7.5 kilometers per second, SPCX employs sophisticated GNSS-based Doppler pre-compensation and timing advance algorithms to mitigate severe frequency shifts and signal latency28. This technological capability is reinforced by the $17 billion acquisition of EchoStar's AWS-4 and H-Block spectrum (1.9–2.0 GHz), which transitions Starlink from a rural broadband provider to a global telecom infrastructure platform The Super Intelligence (SI) segment, formed through the consolidation of xAI, X Corp, and Anysphere, represents the company's highest-growth vector. The SI segment monetizes the Colossus supercomputing clusters, the Grok family of large language models, and the Cursor integrated development environment (IDE)1. The recent launch of Grok 4.7, which features a 500,000-token context window and aggressive 2/6 per million token API pricing, is specifically tailored to dominate agentic software engineering tasks alongside the Cursor user base

  • S2026 · E192
    October 25 · 45 min

    2026Q3 Bloom Energy Corporation

    Bloom Energy Corporation designs, manufactures, and deploys stationary solid oxide fuel cell (SOFC) systems (Bloom Energy Servers) and solid oxide electrolyzer cells (SOEC). The underlying technology converts input fuels—primarily natural gas, biogas, or hydrogen—into electricity via an electrochemical process rather than combustion, virtually eliminating criteria pollutants such as nitrogen oxides (NOx) and sulfur oxides (SOx)17.

  • S2026 · E191
    October 22 · 37 min

    2026Q3 Intuitive Surgical Inc. (ISRG(

    Intuitive Surgical operates as the dominant pioneer in the robotic-assisted surgery (RAS) industry. The company's economic moat is characterized by exceptionally high switching costs, a vast installed base of over 13,200 systems, and a highly integrated ecosystem of recurring revenue streams3. The core business operates through three primary segments: Systems (capital equipment), Instruments and Accessories (I&A - recurring consumables), and Services (recurring maintenance and analytics). The deliberate transition from a pure capital-sales model to an operating-lease and recurring-revenue model has structurally fortified the quality of Intuitive’s earnings. As of Q3 2026, recurring revenue constituted 84% of total sales7. The introduction of the da Vinci 5 system serves as a major catalyst. Featuring 10,000x the computing power of its predecessor, the da Vinci 5 integrates proprietary Force Feedback (FFB) technology6. Peer-reviewed clinical data indicates that FFB reduces the average force applied to tissues during surgery, minimizing trauma and shortening recovery times, which reinforces the clinical value proposition against traditional laparoscopy Despite the expiration of foundational patents that originally insulated the da Vinci architecture, Intuitive has maintained its moat through iterative innovation, aggressive intellectual property defense, a vast network of trained surgeons (over 18,000 trained on da Vinci 5 alone since launch), and substantial regulatory barriers3. The primary fundamental headwind facing the firm is the rapid adoption of GLP-1 receptor agonists (e.g., semaglutide), which have caused a deceleration in bariatric surgery volumes18. However, the overall impact is partially offset by double-digit growth in general surgery, oncology, and the rapid expansion of the Ion endoluminal system for lung biopsies, which saw procedure growth of 31% in the latest quarter

  • S2026 · E190
    October 22 · 42 min

    2026Q3 RTX Corporation (RTX)

    Fundamental and Business Analysis RTX Corporation operates as a premier global aerospace and defense conglomerate, formed by the 2020 merger of Raytheon Company and United Technologies Corporation's aerospace businesses. The company is structured into three principal segments: Collins Aerospace, Pratt & Whitney, and Raytheon Collins Aerospace is a leading provider of technologically advanced aerospace and defense products. Its portfolio includes aerostructures, avionics, interiors, mechanical systems, and mission systems. The segment benefits from highly recurring commercial aftermarket revenues. In Q3 2026, Collins delivered adjusted sales of $8.4 billion, up 10% year-over-year, driven heavily by a 23% increase in commercial original equipment (OE) and a 9% increase in commercial aftermarket sales14. The ongoing recovery in global widebody and narrowbody flight hours serves as a structural tailwind for this segment. Pratt & Whitney (P&W) designs, manufactures, and services aircraft engines and auxiliary power systems. P&W's flagship product is the PW1000G Geared Turbofan (GTF) engine, which powers the Airbus A320neo, Airbus A220, and Embraer E-Jets E216. While the GTF delivers superior fuel efficiency, it has been plagued by a rare powder-metal contamination issue that originated between 2015 and 2021, leading to accelerated inspections and a peak grounding of approximately 650 aircraft17. RTX recognized a massive $3 billion charge in Q3 2023 to account for airline compensation and repair costs18. However, as of Q3 2026, the segment is recovering; MRO (Maintenance, Repair, and Overhaul) output for the PW1100G increased by 35% year-over-year, and commercial aftermarket sales surged 21%19. The segment also produces the F135 engine for the F-35 Lightning II, which is undergoing an Engine Core Upgrade (ECU) to support future Block 4 capabilities. Raytheon focuses on offensive and defensive threat detection, interceptors, and space systems. Key programs include the Patriot missile defense system, AMRAAM, Tomahawk, and the Lower Tier Air and Missile Defense Sensor (LTAMDS)20. Q3 2026 sales for Raytheon reached $8.0 billion, up 14% year-over-year15. The segment is currently benefiting from heightened global defense spending and the replenishment of munitions utilized in recent geopolitical conflicts. Industry Trends and Moat: The aerospace and defense industry is characterized by steep barriers to entry, highly consolidated supply chains, massive capital intensity, and extensive regulatory hurdles. These factors constitute a "wide economic moat" for RTX. The company's competitive advantage is anchored in its massive installed base—for instance, over 71,000 P&W engines worldwide—which guarantees decades of high-margin aftermarket service revenues20. Furthermore, RTX holds sole-provider status on critical defense infrastructure, such as the U.S. Navy's Cooperative Engagement Capability (CEC), which it has supplied since 1985.

  • S2026 · E189
    October 21 · 45 min

    2026Q2 CRISPR Therapeutics AG

    Incorporated on October 28, 2013, as a Swiss stock corporation (Aktiengesellschaft) under the name Inception Genomics AG (renamed CRISPR Therapeutics AG on April 28, 2014) and headquartered at Baarerstrasse 14 in Zug, Switzerland, with primary research and development operations in Boston and Framingham, Massachusetts, CRISPR Therapeutics AG is a commercial-stage biotechnology company developing transformative gene-based medicines21. Although domiciled in Switzerland, the company files domestic U.S. GAAP periodic reports (Forms 10-K, 10-Q, and 8-K) with the U.S. Securities and Exchange Commission as a well-known seasoned issuer The company's foundational technology is built upon Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a bacterial adaptive immune mechanism programmed to cleave double-stranded genomic DNA at precise target sequences25. Co-founder Dr. Emmanuelle Charpentier, alongside Dr. Jennifer Doudna, was awarded the 2020 Nobel Prize in Chemistry for elucidating the CRISPR/Cas9 gene-editing mechanism12. CRISPR Therapeutics holds exclusive therapeutic rights to Dr. Charpentier's foundational patent estate and has expanded its technological architecture to include next-generation base and gene-correction platforms (CRISPR-X and SyNTase), lipid nanoparticle (LNP) in vivo delivery vehicles, allogeneic cell engineering, and small interfering RNA (siRNA) therapeutics2

  • S2026 · E188
    October 20 · 58 min

    20260930 A Review of "Economic Scenarios for Transformative, an Anthropic Working Paper

    Anton Korinek, Charles I. Jones, Szymon Sacher, Tess Cotter, and Peter McCrory The Anthropic Institute Working Paper No. 2026-02 September 2026 This is an AI generated review of a paper by economists from Anthropic that presents a framework for assessing the economic consequences of AI between 2026 and 2030. In the model, AI automates a growing share of cognitive work, raising productivity and displacing workers whomust search for jobs in other occupations. The model maps future paths of AI capabilities into implied paths for GDP, the labor share, wages, labor reallocation, and unemployment. They illustrate the framework by considering three scenarios: modest, substantial, and extreme. Under modest change, AI adds less than half a point to GDP growth by 2030 and raises unemployment by a tenth of a point. In the extreme change scenario, AI has transformative effects, with AI performing almost half of today’s cognitive work by 2030. GDP growth then rises to 15 percent per year, the labor share of income falls from 60 to 45 percent, and nearly one in five cognitive workers is unemployed. We also surveyed US adults about their expectations for AI. Views vary widely, but the median respondent’s answers are consistent with our substantial change scenario in which, by 2030, GDP rises by 8 percent and cognitive employment declines by 4 percent. The model offers a structured way to compare possibilities for our economic future under different expectations about AI.

  • S2026 · E186
    October 16 · 54 min

    2026Q2 Boston Scientific Corporation (BSX) (Updated)

    Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices utilized across a broad spectrum of interventional medical specialties, distributing products to hospitals, clinics, and outpatient centers in 127 countries via direct sales forces and distributor networks1. Management operates the enterprise around five core strategic imperatives: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth, and Develop Key Capabilities28. In the fourth quarter of 2025, Boston Scientific executed an organizational realignment that combined its legacy Cardiology and Peripheral Interventions businesses into a single Cardiovascular segment, operating alongside its MedSurg segment1. In the second quarter of 2026, Cardiovascular generated 67% of total net sales ($1,818 million)9. The Cardiovascular segment accounted for 66% of FY 2025 revenue and 67% of Q2 2026 revenue. Operations in this segment span five primary franchises: The MedSurg segment accounted for 34% of FY 2025 revenue and 33% of Q2 2026 revenue across three specialized franchises: Neuromodulation ($341 million in Q2 2026): Offers WaveWriter Spinal Cord Stimulator (SCS) Systems with FAST Therapy (expanded FDA approval in Q1 2024 for non-surgical chronic low back and leg pain), the Intracept Intraosseous Nerve Ablation System for vertebrogenic back pain, G4 Radiofrequency Ablation (RFA) generators, peripheral nerve stimulation via Nalu Medical, and Vercise Genus Deep Brain Stimulation (DBS) systems for Parkinson's disease9.

  • S2026 · E185
    October 15 · 57 min

    2026Q2 Shopify Inc. (SHOP)

    Shopify Inc. provides cloud-based, multi-channel commerce infrastructure designed to allow merchants of all sizes—from first-time entrepreneurs to global enterprise brands—to start, scale, market, and operate retail businesses across web, mobile, social media, marketplaces, brick-and-mortar point-of-sale (POS), and business-to-business (B2B) channels19. The platform powers over 6.5 million active storefronts across more than 175 countries, with a highly diversified merchant base in which no single merchant has ever accounted for more than 5% of total consolidated revenue in a single reporting period20. Shopify generates revenue through two synergistic operating components: Subscription Solutions and Merchant Solutions19. Subscription Solutions accounted for 22.4% of Q2 2026 revenue and 23.8% of FY2025 revenue, generating recurring revenue through monthly and annual platform subscription plans (Basic, Grow/Shopify, Advanced, and enterprise-grade Shopify Plus), POS Pro subscriptions, variable platform fees, and revenue-sharing arrangements from the sale of themes, domain names, and more than 21,000 third-party applications in the Shopify App Store1. Subscription Solutions serves as the high-margin customer acquisition funnel for the enterprise, consistently delivering gross margins near 80%, specifically 79.7% in Q2 2026 and 81.1% in FY20251. Merchant Solutions accounted for 77.6% of Q2 2026 revenue and 76.2% of FY2025 revenue, generating usage-based, transaction-linked revenue that scales directly with merchant Gross Merchandise Volume (GMV)1. The primary revenue driver within this segment is Shopify Payments, a fully integrated payment processing service that reached 68% GMV penetration in Q2 2026, up from 65% in Q3 2025 and 67% in Q1 202622. Additional Merchant Solutions offerings include Shop Pay, an accelerated consumer checkout network achieving approximately 72.5% checkout completion rates versus an industry average of roughly 62.6%23; Shopify Capital, which provides working capital loans and merchant cash advances and stood at $2,184 million net on the balance sheet as of June 30, 20261; Shopify Markets, which facilitates cross-border duties, tax calculation, and localization powered in part by Global-e16; Shopify Shipping; POS hardware sales; and partner referral fees25. Because payment processing incurs direct interchange and card network assessment fees, Merchant Solutions carries a lower structural gross margin of 38.4% in Q2 2026 and 37.7% in FY20251.

Showing 1–20 of 77 episodes